Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma

Fish, James E.; Karpel, Jill P.; Craig, Timothy J.; Bensch, George; Noonan, Michael; Webb, David; Silverman, Bernard A.; Schenkel, Eric; Rooklin, Anthony R.; Ramsdell, Joe; Nathan, Robert A.; Leflein, Jeffrey; Grossman, Jay; Graft, David F.; Gower, Richard; Garay, Stuart M.; Frigas, Evangelo; DeGraff, Arthur C.; Bronsky, Edwin A.; Bernstein, David I.; Berger, William; Shneyer, Lucy; Nolop, K. B.; Je, Harrison

doi:10.1067/mai.2000.110798

Cited by 65 publications

(42 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a 9-month continuation of the previously described study (37), most of the patients who switched from placebo to open-label treatment with MF-DPI were able to further reduce prednisone use. All patients enrolled in this extension phase (n = 128) initially took MF-DPI 800 μg b.i.d., and the dosage was reduced to 600 or 400 μg b.i.d., as allowed.…”

Section: Patients With Severe Asthmamentioning

confidence: 94%

“…Due to the many adverse effects related to systemic exposure with OCS, especially with long-term use, OCS sparing by means of ICS therapy is desirable. The OCSsparing effects of MF-DPI 400 μg and 800 μg twice daily compared with placebo were evaluated in a 12-week study enrolling 132 patients (Table 1) (37). Both doses of MF-DPI were found to substantially reduce the need for oral prednisone (Figure 4) while also improving lung function, symptom control, and health-related quality of life (HRQOL).…”

Section: Patients With Severe Asthmamentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy and Safety of Mometasone Furoate Delivered via a Dry Powder Inhaler for the Treatment of Asthma

Meltzer

Wenzel

2006

Journal of Asthma

View full text Add to dashboard Cite

Inhaled corticosteroids are the gold standard of daily therapy for effective control of all stages of persistent asthma. For this review of the new inhaled corticosteroid mometasone furoate, a MEDLINE/PubMed search using the terms "mometasone furoate AND asthma" found 57 articles, 17 of which presented data from efficacy and safety studies reviewed herein. In clinical trials, once-daily evening dosing of mometasone furoate delivered via dry powder inhaler (200 or 400 mu g/day) was effective in patients with mild to moderate asthma previously treated with short-acting beta2-agonists alone and in those previously maintained on inhaled corticosteroid therapy. In patients with severe asthma, mometasone furoate 400 mu g twice daily eliminated or reduced the need for oral prednisone while improving lung function, asthma symptoms, and quality of life. Clinical studies have shown that mometasone furoate is generally well tolerated and has minimal systemic activity at recommended doses. In conclusion, mometasone furoate provides primary care and specialty physicians with a safe, effective, and convenient option to meet the challenges of asthma management.

show abstract

Section: Patients With Severe Asthmamentioning

confidence: 94%

Section: Patients With Severe Asthmamentioning

confidence: 99%

The Efficacy and Safety of Mometasone Furoate Delivered via a Dry Powder Inhaler for the Treatment of Asthma

Meltzer

Wenzel

2006

Journal of Asthma

View full text Add to dashboard Cite

show abstract

“…It is only in highly select groups of patients with such severe asthma requiring chronic oral corticosteroids that very high doses of inhaled corticosteroids seem to provide additional benefits to improving lung function, symptom control, quality of life and the ability to reduce oral corticosteroids. 14,15 Similarly, the clinically relevant risks of systemic adverse effects from the long-term use of inhaled corticosteroids are less than generally perceived. Inhaled corticosteroids are known to suppress the hypothalamic-pituitary-adrenal axis, but are very rarely the cause of clinically recognizable adrenal insufficiency.…”

Section: Introductionmentioning

confidence: 99%

Categorizing Asthma Severity: An Overview of National Guidelines

Colice¹

2004

Clinical Medicine & Research

View full text Add to dashboard Cite

“…Attempts to minimise the potential for such side-effects have led to the development of a new generation of corticosteroid drugs that display not only increased potency but also faster clearance rates from the systemic circulation. Forefront among this new generation of corticosteroids are fluticasone propionate (FP) [7] and mometasone furoate (MF) [8,9], and these agents are now being widely promoted for use in both intranasal and inhaled formulations to treat a number of inflammatory disorders of the respiratory tract [10,11].…”

mentioning

confidence: 99%

Mometasone furoate is a less specific glucocorticoid than fluticasone propionate

Austin¹,

Maschera²,

Walker³

et al. 2002

Eur Respir J

View full text Add to dashboard Cite

Fluticasone propionate (FP) and mometasone furoate (MF) are potent synthetic corticosteroids that are widely used as anti-inflammatory agents to treat respiratory diseases. As part of the assessment of the potential for side-effects associated with their use, their activities, not only at the glucocorticoid receptor (GR) but also at the other members of the steroid nuclear receptor family, have been compared.Cell-based functional systems were established to measure different aspects of GR function, as well as the activity at all the other steroid nuclear receptors.The effects of MF and FP on the GR were potent and indistinguishable. Neither corticosteroid showed any activity at the oestrogen receptor, while both were weak antagonists of the androgen receptor. FP was a relatively weak agonist of the progesterone receptor but MF was a very potent agonist of the progesterone receptor, giving activity at similar concentrations to those that stimulate the GR (concentration generating 50% maximal effect (EC50)=50 pM). Moreover, while FP was a weak antagonist of the mineralocorticoid receptor (concentration generating 50% maximal inhibitory effect=80 nM), MF displayed potent partial agonist activity (EC50=3 nM, 30%).

show abstract

Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma

Cited by 65 publications

References 20 publications

The Efficacy and Safety of Mometasone Furoate Delivered via a Dry Powder Inhaler for the Treatment of Asthma

The Efficacy and Safety of Mometasone Furoate Delivered via a Dry Powder Inhaler for the Treatment of Asthma

Categorizing Asthma Severity: An Overview of National Guidelines

Mometasone furoate is a less specific glucocorticoid than fluticasone propionate

Contact Info

Product

Resources

About